[
  {
    "ts": null,
    "headline": "Looking at the Narrative for Quest Diagnostics as Growth Outlook and Analyst Views Evolve",
    "summary": "Quest Diagnostics has seen its Fair Value Estimate rise slightly, climbing from $188.19 to $191.56 per share as analysts factor in updated growth expectations. This change is supported by increased revenue growth projections, reflecting renewed optimism in the company's outlook following recent research and 2025 guidance updates. Stay tuned to discover how investors can monitor ongoing updates and shifts in Quest's evolving narrative. What Wall Street Has Been Saying Analyst sentiment...",
    "url": "https://finnhub.io/api/news?id=4b001cdc1f7146dc13fc82aa8d7b54d6b0d7eae5de3e89cbadf9fe8496e07761",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760789264,
      "headline": "Looking at the Narrative for Quest Diagnostics as Growth Outlook and Analyst Views Evolve",
      "id": 137165611,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics has seen its Fair Value Estimate rise slightly, climbing from $188.19 to $191.56 per share as analysts factor in updated growth expectations. This change is supported by increased revenue growth projections, reflecting renewed optimism in the company's outlook following recent research and 2025 guidance updates. Stay tuned to discover how investors can monitor ongoing updates and shifts in Quest's evolving narrative. What Wall Street Has Been Saying Analyst sentiment...",
      "url": "https://finnhub.io/api/news?id=4b001cdc1f7146dc13fc82aa8d7b54d6b0d7eae5de3e89cbadf9fe8496e07761"
    }
  }
]